PLOD1 and polycystic ovary syndrome: All doses evaluated in this study had similar effects on the hormonal levels measured, suggesting the possibility that a lower dose of elagolix or a different dosing regimen for patients with PCOS could reduce LH tone a bit less profoundly and lead to the clinical goals set for this study.